Company Overview
Tvardi Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on the development of novel, oral, and small molecule therapies that target STAT3 to address fibrosis-driven diseases with significant unmet need in the United States. The company functions within the Healthcare sector and specifically within the Biotechnology industry, positioning itself to leverage scientific advancements in drug discovery for therapeutic applications. Currently, the enterprise maintains a market capitalization of $29.74M and employs a workforce of 12 individuals to advance its research and development pipeline. The market capitalization figure indicates that the company is in an early-stage growth phase typical for clinical-stage entities, where valuation is driven by potential future clinical outcomes rather than current cash flows, while the lack of annual revenue data underscores the company's status as a pre-revenue biotechnology firm that has not yet generated commercial sales from its product candidates.
Financial Health
Tvardi Therapeutics, Inc. reports a net income of $-23,646,000 and an EBITDA of $-29,868,000 for the trailing twelve-month period, while its revenue is listed as N/A due to its clinical-stage development status. The substantial gap between the reported net income and the more negative EBITDA reveals a significant cost structure burden related to non-operating expenses, likely including interest or tax adjustments, which further erodes profitability in the absence of commercial revenue. The company generated free cash flow of $-12,512,875, a metric that indicates a high burn rate typical of early-stage biotechnology firms and necessitates continuous access to capital markets or existing reserves to sustain operations. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which is consistent with companies that have not yet achieved commercial product launches or sales volume to generate positive gross revenue. On the balance sheet, the company holds cash of $36.46M against a debt level of $228,000, resulting in a debt-to-equity ratio of 0.82, which suggests a balance sheet that is not highly leveraged but still carries some financial obligations. The current ratio stands at 3.48, indicating strong short-term liquidity and the ability to cover current liabilities more than three times with available current assets. Additionally, the return on equity is -135.6% and the return on assets is -72.7%, metrics that reveal that management effectiveness is currently measured by capital preservation and research progress rather than profit generation, as the negative returns reflect the company's investment phase where capital is consumed to develop assets rather than returning value through earnings.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E is -1.50, a valuation dynamic that implies expected earnings trajectory remains undefined until the company transitions from clinical development to commercialization and begins generating net income. The price-to-book ratio is 1.07, indicating that the market values the company at a slight premium over its book value, which often occurs when investors assign value to the intangible assets and intellectual property inherent in biotechnology firms despite current losses. The price-to-sales ratio is N/A and the EV/EBITDA is 0.22, suggesting that traditional multiple-based valuation methods are not applicable due to the lack of sales, while the low EV/EBITDA reflects the company's high negative earnings relative to its enterprise value. The stock has traded between a 52-week high of $43.65 and a 52-week low of $3.15, creating a range where the current price sits significantly below the high but above the low, highlighting the extreme volatility and potential for re-rating based on clinical trial data. The beta value is N/A, meaning that the company's price volatility relative to the broader market cannot be quantified using standard beta metrics, likely due to the low market capitalization and the idiosyncratic risks associated with the biotechnology sector.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both N/A, indicating that there are no historical commercial data points to compare against, which prevents an analysis of whether earnings are growing faster or slower than revenue in a commercial context. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as the payout ratio is listed as 0.0% and the dividend yield is N/A, reflecting a strategy where the company reinvests all available capital into research, development, and clinical trials rather than paying dividends to shareholders. This reinvestment approach is standard for clinical-stage biopharmaceutical companies that must prioritize funding for their lead product candidates, such as TTI-101, to advance through clinical phases and eventually reach the market. Consequently, the overall growth and income profile is characterized by a complete reliance on future commercial potential and clinical success metrics rather than current cash generation, dividend income, or established revenue growth rates.